GlassScriptPhysician profile
Aubrey Garner
NPI 1689322018
$5,585.68
in general payments reported to CMS, 2019-2025
23 companies · $2,701 in 2025
The $2,701 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $58.65 · 2024: $2,826 · 2025: $2,701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,433 · Education: $94.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,432.79 |
| Education | $94.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,438.94 | 2024-2025 | |
| Amgen INC. | $792.83 | 2024-2025 | Enbrel, Krystexxa, Otezla |
| Janssen Biotech, INC. | $571.50 | 2024-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $317.58 | 2024-2025 | Orencia |
| Mallinckrodt Hospital Products INC. | $302.68 | 2024-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $246.96 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $234.92 | 2024 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $223.51 | 2024-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $214.84 | 2024-2025 | Benlysta |
| Pfizer INC. | $196.07 | 2024-2025 | |
| Sobi, INC | $179.94 | 2024-2025 | Kineret |
| Ucb, INC. | $164.88 | 2024-2025 | Bimzelx, Cimzia |
| Ani Pharmaceuticals, INC. | $120.21 | 2024-2025 | Purified Cortrophin Gel |
| Radius Health, INC. | $112.38 | 2024-2025 | Tymlos |
| Organon LLC | $98.34 | 2022-2025 | Hadlima, Renflexis |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $79.94 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $74.99 | 2024 | |
| Genentech USA, INC. | $60.76 | 2024-2025 | Actemra |
| Invivyd INC | $58.22 | 2025 | Pemgarda |
| Lilly USA, LLC | $41.92 | 2024 | Taltz |
| Actelion Pharmaceuticals US, INC. | $23.50 | 2025 | Opsumit, Uptravi |
| Alexion Pharmaceuticals, INC. | $15.75 | 2025 | Strensiq |
| Fresenius Kabi USA, LLC | $15.02 | 2025 | Tyenne |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aubrey Garner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.